Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Jennifer K. Litton; Sara A. Hurvitz; Lida A. Mina; Hope S. Rugo; Ki Hoon Lee; Anthony Gonçalvès; Sami Diab; Natasha Woodward; Annabel Goodwin; Rinat Yerushalmi; Henri Roché; Young‐Hyuck Im; W. Eiermann; Ruben G.W. Quek; Tiziana Usari; Silvana Lanzalone; Akos Czibere; Joanne L. Blum; Miguel Martín; Johannes Ettl

doi:10.1016/j.annonc.2020.08.2098

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In gBRCA1/2-mutated HER2-negative ABC, talazoparib did not significantly improve OS over chemotherapy; subsequent treatments may have impacted analysis. Safety was consistent with previous observations. PRO continued to favor talazoparib.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Litton et al. (2020) studied this question.

synapsesocial.com/papers/69d70aca99397875bbaa82c5 https://doi.org/10.1016/j.annonc.2020.08.2098

View Full Paper

Ask AI

Bookmark

Share

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Ask about this paper

Abstract

Discussion

Cite This Study

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading